Feasibility of NIV-NAVA as a primary respiratory support and its clinical impacts in a targeted group of preterm infants: protocol for a prospective observational study Authors: Hannah Cho, Young Hwa Jung, Jiseon Park, Hyo Ju Yang, Mi Jin Kim, Juyoung Lee Published: 2026 ABSTRACT AbstractIntroductionNon-invasive neurally adjusted ventilatory assist (NIV-NAVA) is a promising respiratory support method for avoiding invasive mechanical ventilation in neonatal intensive care units (NICUs). However, its effectiveness and safety have not been widely established through clinical evidence. In this study, we aim to evaluate the feasibility of NIV-NAVA as a primary respiratory support method after birth and its effects on short-term clinical outcomes and long-term neurodevelopment in preterm infants.Methods and analysisIn this prospective multicentre observational study, 230 preterm infants will be recruited after birth. This study will include preterm infants born between 27+0 and 31+6 weeks of gestation who require respiratory support within the first 48 hours after birth. NIV-NAVA will be initiated as primary respiratory support either immediately after birth or during the early NICU stay, with settings adjusted according to each infant’s clinical condition. Discontinuation of NIV-NAVA or transition to continuous positive airway pressure or high-flow nasal cannula will be performed based on clinical stability. A less invasive surfactant administration method will be used for infants with respiratory distress syndrome to avoid intubation whenever possible. Infants intubated at birth will be extubated to NIV-NAVA as early as is clinically feasible. Invasive ventilation may be applied if clinical deterioration occurs. The rate of NIV-NAVA failure, duration of non-invasive and invasive ventilation, rate of bronchopulmonary dysplasia and clinical outcomes, such as air leak, patent ductus arteriosus, intraventricular haemorrhage and retinopathy of prematurity, will be measured. The neurodevelopmental outcomes of infants will be assessed for up to 3 years.Ethics and disseminationThe Institutional Review Board (IRB) of Korea University Anam Hospital (2024AN0554) and Seoul National University Bundang Hospital (IRB No. B-2507-984-304) approved this study. The results will be disseminated through scientific conferences and publications.Trial registration numberNCT06786039 registered on 14 January 2025.Keywords: Preterm Infants, Noninvasive Ventilation, Interactive Ventilatory Assist, Child Development STRENGTHS AND LIMITATIONS OF THIS STUDY This prospective, multicentre, observational longitudinal study enhances the external validity and generalisability of the findings across diverse clinical environments. This prospective, multicentre, observational longitudinal study enhances the external validity and generalisability of the findings across diverse clinical environments. The selective inclusion of preterm infants (27 weeks 0 days to 31 weeks 6 days) requiring early respiratory support allows for the targeted evaluation of a clinically significant high-risk population. The selective inclusion of preterm infants (27 weeks 0 days to 31 weeks 6 days) requiring early respiratory support allows for the targeted evaluation of a clinically significant high-risk population. The combined use of non-invasive neurally adjusted ventilatory assist (NIV-NAVA) and less invasive surfactant administration reflects contemporary neonatal respiratory management strategies aimed at optimising patient-ventilator synchrony and minimising ventilator-induced lung injury by avoiding invasive mechanical ventilation. The combined use of non-invasive neurally adjusted ventilatory assist (NIV-NAVA) and less invasive surfactant administration reflects contemporary neonatal respiratory management strategies aimed at optimising patient-ventilator synchrony and minimising ventilator-induced lung injury by avoiding invasive mechanical ventilation. Although an observational design without randomisation limits causal inference and may be influenced by confounding factors, it provides valuable real-world evidence regarding the feasibility and clinical outcomes of NIV-NAVA. Although an observational design without randomisation limits causal inference and may be influenced by confounding factors, it provides valuable real-world evidence regarding the feasibility and clinical outcomes of NIV-NAVA. The limited sample size and potential inter-centre variability may reduce the statistical power, while follow-up attrition and assessment bias could affect the reliability of the neurodevelopmental outcome data. The limited sample size and potential inter-centre variability may reduce the statistical power, while follow-up attrition and assessment bias could affect the reliability of the neurodevelopmental outcome data. Introduction Despite the declining birth rate worldwide, the number and proportion of preterm births are increasing. In particular, very preterm infants born at less than 32 weeks of gestation and requiring neonatal intensive care are at a high risk for growth and neurodevelopmental issues.1 As recent advancements in neonatal intensive care have improved the survival rate of preterm infants, long-term morbidities have also become an important factor in ensuring that these infants grow into healthy members of society. Neurally adjusted ventilatory assist (NAVA) is a mechanical ventilation method that adjusts the degree and timing of ventilatory assistance based on an infant’s neural respiratory drive.2 Inspiratory signals from the respiratory centre are converted into electrical activity of the diaphragm (Edi) through the phrenic nerve, which determines the initiation, intensity and duration of inspiration and expiration.2 3 This mechanism prevents excessive or insufficient respiratory assistance, improves patient-ventilator synchrony and reduces the mismatch between spontaneous breathing and mechanical ventilation.24,6 Non-invasive NAVA (NIV-NAVA) provides respiratory assistance through nasal prongs or masks instead of an intra-tracheal tube.7 Non-invasive respiratory support reduces ventilator-induced lung injury by preventing invasive mechanical ventilation.8 Combining non-invasive support with NAVA is thought to be more beneficial in decreasing immediate respiratory severity and apnoea in preterm infants.9 10 However, evidence regarding the clinical outcomes of NIV-NAVA in preterm infants remains limited and long-term outcomes are currently lacking. In this study, we aim to investigate the clinical outcomes associated with the use of NIV-NAVA in preterm infants in a focused group of infants born between 27 and 31 weeks of gestation in neonatal intensive care units (NICUs). The primary goal of this study is to determine the feasibility of NIV-NAVA as the primary respiratory support method immediately after birth. We will also explore the impact of this NIV-NAVA application on short-term clinical outcomes and long-term neurodevelopment in this targeted group of preterm infants. Methods and analysis Study design This is a prospective observational study involving preterm infants born between 27+0 and 31+6 weeks of gestation who require respiratory support within the first 48 hours of life. Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination of this research. Outcome measures Primary outcome: Primary outcome: Rate of NIV-NAVA failure—endotracheal intubation (except brief intubation for surfactant administration or surgical procedures requiring general anaesthesia). 2 1Secondary outcomes: Secondary outcomes: Bronchopulmonary dysplasia rate at 36 weeks’ postmenstrual age defined by the Jensen Criteria.11 Bronchopulmonary dysplasia rate at 36 weeks’ postmenstrual age defined by the Jensen Criteria.11 Duration of non-invasive ventilation (NIV-NAVA, nasal continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC)). Duration of non-invasive ventilation (NIV-NAVA, nasal continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC)). Duration of invasive ventilation. Duration of invasive ventilation. Air leaks such as pneumothorax or pulmonary interstitial emphysema. Air leaks such as pneumothorax or pulmonary interstitial emphysema. Patent ductus arteriosus requiring treatment (except prophylactic treatment). Patent ductus arteriosus requiring treatment (except prophylactic treatment). Time to achieve full enteral feeding (100 mL/kg/day). Time to achieve full enteral feeding (100 mL/kg/day). Incidence of grade 2 or higher intraventricular haemorrhage. Incidence of grade 2 or higher intraventricular haemorrhage. Incidence of stage 2 or higher retinopathy of prematurity. Incidence of stage 2 or higher retinopathy of prematurity. Incidence of periventricular leukomalacia. Incidence of periventricular leukomalacia. 3 1Tertiary outcomes (long-term infant outcomes): Tertiary outcomes (long-term infant outcomes): Motor, cognitive and social development of infants measured using the Korean-Bayley Scales of Infant Development Third edition at 18 months of corrected age and 36 months of chronological age.12 Motor, cognitive and social development of infants measured using the Korean-Bayley Scales of Infant Development Third edition at 18 months of corrected age and 36 months of chronological age.12 Autism spectrum screening results measured using the Korean-Modified Checklist for Autism in Toddlers Revised version at 18 months of corrected age.13 Autism spectrum screening results measured using the Korean-Modified Checklist for Autism in Toddlers Revised version at 18 months of corrected age.13 Language abilities of infants measured using the MacArthur-Bates Communication Development Inventory at 18 months of corrected age.14 Language abilities of infants measured using the MacArthur-Bates Communication Development Inventory at 18 months of corrected age.14 Results of infant behaviour assessment using the Korean Child Behavior Checklist at 36 months of chronological age.15 Results of infant behaviour assessment using the Korean Child Behavior Checklist at 36 months of chronological age.15 Measurement of infant language development using the Korean Sequenced Language Scale for Infants at 36 months of chronological age.16 Measurement of infant language development using the Korean Sequenced Language Scale for Infants at 36 months of chronological age.16 Sample size calculation In this prospective observational study, 80 participants in the NICU of Korea University Anam Hospital and 150 participants in the NICU of Seoul National University Bundang Hospital will be recruited over a 2-year period based on the number of previous patients admitted to these NICUs. If other sites are to be included in this study, their sample size will be determined based on the number of previous patients admitted to each NICU. Participants and recruitment A total of 230 participants will be recruited from among eligible infants admitted to the NICU within 48 hours of birth after obtaining written informed consent from their parents. All eligible participants will be screened to determine the target number. Table 1 presents the inclusion and exclusion criteria. Table 1Inclusion and exclusion criteriaInclusion criteriaExclusion criteria Infant Born between 27 weeks 0 days and 31 weeks 6 days of gestation Requirement of respiratory support within 48 hours after birth Infant Congenital anomalies affecting the lungs, heart or other organs that could influence breathing Parents do not consent to participation in the study Inclusion and exclusion criteria Born between 27 weeks 0 days and 31 weeks 6 days of gestation Born between 27 weeks 0 days and 31 weeks 6 days of gestation Requirement of respiratory support within 48 hours after birth Requirement of respiratory support within 48 hours after birth Congenital anomalies affecting the lungs, heart or other organs that could influence breathing Congenital anomalies affecting the lungs, heart or other organs that could influence breathing Parents do not consent to participation in the study Parents do not consent to participation in the study Intervention and observation conditions Respiratory assistance with NIV-NAVA will be initiated within 48 hours of birth in patients requiring respiratory support. Infants will be considered to require respiratory support if they meet one or more of the following criteria: presence of respiratory distress such as tachypnoea, retractions or grunting; requirement for supplemental oxygen to maintain target oxygen saturation (90–95%); recurrent apnoea requiring stimulation and overall clinical assessment. This may occur immediately after birth/admission to the NICU or at a later time. The settings of respiratory support will be adjusted based on the clinical condition of each participant, including oxygen requirement, blood gas parameters and work of breathing. The participants’ vital signs, including oxygen saturation (SpO2), heart rate and respiratory rate, will be continuously monitored using standard bedside monitors in the NICU. Additionally, Edi will be monitored in real time to assess neural breathing patterns and patient-ventilator interactions. The clinical team will regularly verify the quality of the Edi signal, confirm correct catheter placement and ensure acquisition of stable Edi waveforms. Clinical assessments, including work of breathing and lung auscultation, will be performed by nursing and medical staff at least every 2 hours. Blood gas analysis will be conducted as clinically indicated to supplement the continuous monitoring data. Weaning from NIV-NAVA will be performed gradually by stepwise reduction in NAVA levels, guided by clinical stability and Edi activity. NIV-NAVA may be de-escalated to nasal CPAP or HFNC when stability criteria are met, including improved work of breathing (Edi peak <5–15 μV and NAVA level <1.0 cmH2O/μV), not increased oxygen requirement and fewer than two to three episodes of significant apnoea requiring intervention within 24 hours. Discontinuation of respiratory support will be considered when the infant demonstrates sustained clinical stability without signs of respiratory distress and maintains adequate oxygenation and ventilation with minimal support. In cases of respiratory distress syndrome (RDS) requiring a fraction of inspired oxygen >0.3 with clinical symptoms of distress, lung surfactants will be administered via the less invasive surfactant administration method, and endotracheal intubation will be avoided whenever possible. If the participant is intubated in the delivery room immediately after birth, typically according to Neonatal Resuscitation Program (NRP) guidelines (eg, for surfactant administration or sustained positive pressure ventilation), they will receive invasive respiratory support during initial stabilisation and transport to the NICU. The participant will be extubated to NIV-NAVA as soon as possible based on the physician’s judgement. NIV-NAVA failure is defined as the need for escalation to endotracheal intubation during NIV-NAVA application and the initiation of invasive mechanical ventilation based on clinical criteria, including persistent hypoxaemia despite increasing support, respiratory acidosis, recurrent apnoea requiring intervention or overall clinical deterioration. The decision to intubate will be made at the discretion of the attending physician. The ventilator strategies to be used in this study are shown in figure 1. Ventilator strategies during the study. Edi, electrical activity of the diaphragm; FiO2, fraction of inspired oxygen; GA, gestational age; HFNC, high-flow nasal cannula; HFOV, high-frequency oscillatory ventilation; LISA, less invasive surfactant administration; NAVA, neurally adjusted ventilatory assist; N-CPAP, nasal continuous positive airway pressure; NICU, neonatal intensive care unit; NIV, non-invasive; NRP, Neonatal Resuscitation Program; PIP, peak inspiratory pressure. Baseline clinical data of the infants at the time of participant registration will include the following: Maternal data including age, address, history of infertility treatment, medical history (chronic hypertension and diabetes), obstetric history, parity, gravidity, antenatal antibiotics (type and duration of antibiotics used), other medications, preeclampsia, gestational diabetes, rupture of membranes and its duration, oligohydramnios, chorioamnionitis, umbilical cord infection, mode of delivery and other medical histories. Maternal data including age, address, history of infertility treatment, medical history (chronic hypertension and diabetes), obstetric history, parity, gravidity, antenatal antibiotics (type and duration of antibiotics used), other medications, preeclampsia, gestational diabetes, rupture of membranes and its duration, oligohydramnios, chorioamnionitis, umbilical cord infection, mode of delivery and other medical histories. Neonatal data including date and time of birth, sex, gestational age, birth weight, length, head circumference, small-for-gestational-age or large-for-gestational-age, neonatal resuscitation details, Apgar score, presence of RDS, number of surfactant administrations, date and time to start NIV-NAVA application, and date and time of surfactant administration. Neonatal data including date and time of birth, sex, gestational age, birth weight, length, head circumference, small-for-gestational-age or large-for-gestational-age, neonatal resuscitation details, Apgar score, presence of RDS, number of surfactant administrations, date and time to start NIV-NAVA application, and date and time of surfactant administration. Timeline Table 2 presents an overview of the timelines. Table 2Overview of the study scheduleVisitEnrollmentBaselineShort-term outcomeLong-term outcomeNICU admissionNICU discharge18 months CA(16–20 months CA)36 months(33–39 months)Informed consentXInclusion/exclusion criteriaXBasic clinical informationXClinical outcomesXNeurodevelopmental outcomesX*†‡X*§¶*Korean-Bayley Scales of Infant Development Third version (K-BSID III).†Korean-Modified Checklist for Autism in Toddlers (K-M-CHAT).‡MacArthur-Bates Communication Development Inventory (MB-CDI-K).§Korean Child Behavior Checklist (K-CBCL).¶Korean Sequenced Language Scale for Infant (K-SELSI).CA, corrected age; NICU, neonatal intensive care unit. Overview of the study schedule Korean-Bayley Scales of Infant Development Third version (K-BSID III). Korean-Modified Checklist for Autism in Toddlers (K-M-CHAT). MacArthur-Bates Communication Development Inventory (MB-CDI-K). Korean Child Behavior Checklist (K-CBCL). Korean Sequenced Language Scale for Infant (K-SELSI). CA, corrected age; NICU, neonatal intensive care unit. Data handling and confidentiality All study data will be recorded using electronic case record forms. Data corrections will be performed according to the manufacturer’s instructions and timeline. The collected data will be reviewed in detail. Each data collection form and the specific information required will be discussed in detail on an item-by-item basis. The training sessions will also address data entry processes, data discrepancy queries and best practices to ensure high-quality research data. Data integrity will be ensured through password protection, referential data rules, range checks and consistency checks during data entry and storage. Any data modifications will be documented through a data change or inquiry system. The data entered into the database will be accessible for review through a data entry application, with user activities regulated according to the privileges assigned to their unique user identification codes and passwords. Data errors will be identified using programmes designed to detect missing and erroneous data. These errors will be summarised with detailed descriptions in the Data Query Reports, which will be forwarded to the study investigators. Upon receipt of such queries, study personnel will verify inconsistencies by reviewing the original forms and other sources, making necessary corrections and providing responses to queries. Investigators will be required to verify the accuracy of the completed case report forms by signing key documents as appropriate. To maintain confidentiality, the source documents will be securely stored on a locally encrypted server. The only study documents containing the names of the participants will be the enrolment and informed consent forms. Hard copies of the data collection forms will be kept locked when they are not actively used. Access to data files containing personal identification information will be restricted to the principal investigators and essential study personnel. All study-related documentation will be retained for a minimum of 3 years following the completion of the study. Data analysis plan Continuous values will be summarised as means with SD or medians with IQRs. Categorical variables will be summarised as the proportion of participants in each category. Differences between groups of categorical variables will be analysed using the χ2 test or Fisher’s exact test, whereas continuous variables will be assessed using an independent t-test or the Mann-Whitney U test. The level of significance for the study is 5% (two-sided) for all analyses. Study coordination and monitoring Once the participant is enrolled, the study personnel will make every reasonable effort to comply with the study’s ventilator strategies (figure 1) and will follow the infant throughout the study period. The study investigators and staff will provide written feedback on the infant development assessment results. Participants could withdraw from the study at any time for any reason. The investigator may also withdraw participants from the study if they are unwilling or unable to comply with the required procedures after consultation with the study staff. This study will be monitored by the Clinical Trial Center of the Korea University Anam Hospital, Seoul, South Korea. Independent data-monitoring and safety-monitoring committee members will assess patient safety and trial progress every 12 months. Ethics and dissemination The Institutional Review Boards (IRB) of Korea University Anam Hospital (IRB No. 2024AN0554) and Seoul National University Bundang Hospital (IRB No. B-2507-984-304) reviewed and approved this study. Written informed consent will be obtained from the parents of each preterm infant (online supplemental material). All methods will be conducted with strict adherence to the IRB-approved protocol and in full compliance with all pertinent guidelines and regulations in South Korea. The results of this study will be disseminated to the local and global research communities, including the Korean Ministry of Health and Welfare. Dissemination modes will include abstracts, reports and presentations. We will submit separate articles for open-access publication in the relevant journals. Supplementary material Footnotes Funding: This research was supported by a Korea University Anam Hospital Grant (O2617561). Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-114353). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Consent obtained from parent(s)/guardian(s). Ethics approval: This study involves human participants and was approved by Institutional Review Board of the Korea University Anam Hospital (2024AN0554) and Seoul National University Bundang Hospital (IRB No. B-2507-984-304). Participants gave informed consent to participate in the study before taking part. Data availability free text: Data will be made available upon reasonable request. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Data availability statement Data are available upon reasonable request. References Supplementary Materials Data Availability Statement Data are available upon reasonable request.